Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP

Watchlist Manager
Tonix Pharmaceuticals Holding Corp Logo
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
Watchlist
Price: 18.86 USD -2.18% Market Closed
Market Cap: 222.2m USD

Tonix Pharmaceuticals Holding Corp
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Tonix Pharmaceuticals Holding Corp
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
Operating Expenses
-$103.4m
CAGR 3-Years
2%
CAGR 5-Years
-20%
CAGR 10-Years
-9%
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$22.7B
CAGR 3-Years
-2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$11.6B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$13.8B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$5.6B
CAGR 3-Years
-18%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$8.4B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-14%
No Stocks Found

Tonix Pharmaceuticals Holding Corp
Glance View

Market Cap
222.2m USD
Industry
Biotechnology

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 73 full-time employees. The company went IPO on 2010-03-29. The company is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.

TNXP Intrinsic Value
99.24 USD
Undervaluation 81%
Intrinsic Value
Price

See Also

What is Tonix Pharmaceuticals Holding Corp's Operating Expenses?
Operating Expenses
-103.4m USD

Based on the financial report for Sep 30, 2025, Tonix Pharmaceuticals Holding Corp's Operating Expenses amounts to -103.4m USD.

What is Tonix Pharmaceuticals Holding Corp's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-9%

Over the last year, the Operating Expenses growth was -22%. The average annual Operating Expenses growth rates for Tonix Pharmaceuticals Holding Corp have been 2% over the past three years , -20% over the past five years , and -9% over the past ten years .

Back to Top